Devarsh Vakil of HDFC Securities Advises Against Buy on Dips Strategy Amid Market Volatility Leadership Transition at Manchester City Enzo Maresca Poised to Succeed Pep Guardiola Conservative Crypto Options for RiskAware Investors Gain Attention MalaysiaJapan Hydrogen Project Faces ScaleBack Amid Funding Constraints US Banks Report Profit Uptick in First Quarter FDIC Data Shows Nokia Secures UK Appeal Victory Blocking Acer and Asus Video Patent Lawsuits HEI Q4 2025 Earnings EPS Beat Amid Modest Stock Reaction LTC Properties Inc Q1 2026 Earnings EPS Miss Disappoints Despite Resilient REIT Operations Nutrien Ltd NTR Q1 2026 Earnings EPS Misses Estimates by 473 Amid Challenging Market Conditions BRFH Q1 2026 Earnings BetterThanExpected Loss Reduction Drives Stock Uptick FTAIM Q1 2026 Earnings EPS Misses Estimates Amid Challenging Quarter ABTC Q1 2026 Earnings Earnings Miss Amid Significant EPS Surprise Revenue Absent KKRS KKR Subordinated Notes Holds Near 1631 as Low Volatility Persists Support and Resistance Levels in Focus Aditxt Inc ADTX Plunges 1957 Key Support Level Tested at 019 Tenable Holdings TENB Edges Higher as Cybersecurity Demand Remains Strong Aclarion Inc ACON Tests Support Zone After 156 Decline Viavi Solutions VIAV Edges Higher Key Levels in Focus After Modest Gains US Payrolls Surge Past Expectations in April Yet Underlying Red Flags Emerge ATYR Q1 2026 Earnings Narrower Loss Per Share Beats Expectations Stock Dips on Pipeline Update Darling Ingredients DAR Edges Higher as Support Holds Assurant Inc AIZ Q1 2026 Earnings Strong EPS Beat Amid Flat Revenue and Modest Stock Decline ABXL Q1 2026 Earnings InLine EPS Performance Amid Stable Operations UFPI Q1 2026 Earnings EPS Misses Estimates Amid Soft Demand and Margin Compression Pyxis Oncology Q1 2026 Earnings NarrowerThanExpected Loss Drives Positive Market Reaction Textron Q1 2026 Earnings Strong EPS Surprise Drives Modest Stock Gain SRPT Q1 2026 Earnings EPS Smashes Estimates by 1847 as Gene Therapy Execution Drives Profit Surprise PLX Q1 2026 Earnings Massive EPS Surprise as Protalix BioTherapeutics Reports Strong Profitability